 The FDA has signed off Sorrento Therapeutics Incs NASDAQ: SRNE IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor DAR-T Cell therapy for relapsed or refractory multiple myeloma. DAR-T technology is readily adaptable to dozens of cancer targets, and Sorrento has developed a preclinical product pipeline with specific fully human antibodies discovered from Sorrentos G-MAB library. 